PERTH, Australia – On the heels of a A$90 million (US$67.12 million) initial public offering on the Australian Securities Exchange, device company Trajan Group Holdings Ltd. has doubled its share price and is well poised for its next stage of global growth. Trajan makes precision consumable products, devices and solutions that used in analyzing biological samples.

Health-tech startup Doctor Anywhere Ltd. (DA) has raised $88 million in series C fundraising, as the telehealth sector continues to be attractive for investors. The round is one of the largest private investments ever raised by a Southeast Asian digital health company and was led by growth equity investor Asia Partners. Novo Holdings, Philips, OSK-SBI Venture Partners, EDBI, Square Peg, IHH Healthcare, Kamet Capital and Pavilion Capital also participated.

Rokit Healthcare Inc. received approval from South Korea’s Ministry of Food and Drug Safety (MFDS) for Dfurege, its artificial organ platform to treat diabetic foot ulcers. “We hope that having a South Korean approval for this platform will be a boost for our planned IPO,” Seok Hwan You, CEO at Rokit, told BioWorld.

Ventura Capital has led a $60 million series A investment round into consumer genetic testing company Dnanudge Ltd. It is the first major fundraising round for the London-based company, which will be used to accelerate deployment of its DNA testing service worldwide. Dnanudge is aiming to tap into the lucrative consumer DNA testing market with Dnaband, a wearable device that stores digital DNA and helps users make healthier choices by personalizing shopping behaviors. The company is also planning a service for personalized skincare shopping.

Onkos Surgical Inc. nabbed an additional $15 million from its existing investors in a series C fundraising round. The Parsippany, N.J.-based company plans to use the new cash to accelerate research and development for its product line which is designed to meet the specialized needs of oncology patients who require orthopedic surgery and the surgeons who work with them.

Genome Medical Holding Co. put its competitors on notice with two big moves designed to position the company as a leader in genetic testing and virtual genomic care. The company acquired Genematters LLC, a provider of telegenetics counseling, and closed a $60 million series C fundraising round. Together, the moves stand to significantly expand Genome Medical’s digital infrastructure and clinical expertise in genetics services.

China’s ongoing efforts to tighten regulations across the board is hitting medical device companies. Two companies that issued shares in Hong Kong for the first time over the past week saw their shares tumble right out of the gate. Acotec Scientific Holdings Ltd. (HK: 6669) shares fell more than 25% on their first trading day on the Hong Kong Stock Exchange on Aug. 24 amid regulatory changes in China’s health care industry.